Trial · NCT02066792
Dose Timing of D-Cycloserine to Augment CBT for Social Anxiety Disorder
NCT02066792, Early phase 1, Completed, Jasper A. Smits; results first posted 2020-06-09
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Dose Timing of D-Cycloserine to Augment CBT for Social Anxiety Disorder. Trials, record NCT02066792. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02066792
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Dose Timing of D-Cycloserine to Augment CBT for Social Anxiety Disorder
- NCT number
- NCT02066792
- Status
- Completed
- Phases
- Early phase 1
- Enrollment
- 152 participants, actual
- Lead sponsor
- Jasper A. Smits
- Conditions
- Social Anxiety Disorder
- Interventions
- D-Cycloserine, Placebo, Cognitive Behavioral Therapy
- First posted
- 2014-02-20
- Last updated
- 2026-06-15
- Results first posted
- 2020-06-09
Source ClinicalTrials.gov
Registered outcomes1
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Social Anxiety Symptom Severity | Assessments took place at multiple time points from baseline to 3-month follow-up. The three-month is reported | The main outcome was a composite Z-score from the Liebowitz Social Anxiety Scale (LSAS) and the Social Phobic Disorders Severity and Change Form (SPD-SC Form). "The Composite Z-score of the LSAS and SPD-SC Form indicates the number of standard deviations away from the mean. A Z-score of 0 is equal to the mean of a reference population. Negative numbers indicate values lower symptom severity and positive numbers indicate higher symptom severity. The LSAS is a 24-item scale that measures fear and avoidance in social and performance situations within the last week, using 0 (no fear/never avoids) to 3 (severe fear/usually avoids) scale. LSAS scores range from 0-144 with higher scores indicated worse outcomes. The SPD-S is the Clinical Global Impression Scale27 adapted for SAD, which instructs evaluators to use a 7-point scale (1=normal, not at all ill; 7=among the most extremely ill patients) to index the severity of social anxiety. |
Source ClinicalTrials.gov
Outcomes1
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Social Anxiety Symptom Severity | Assessments took place at multiple time points from baseline to 3-month follow-up. The three-month is reported | Intent-to-treat | score on a scale | MEAN |
Source ClinicalTrials.gov
Results by group4
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Social Anxiety Symptom Severity | Tailored Post-Session DCS | -.46 | Standard Error .13 | score on a scale | |
| Social Anxiety Symptom Severity | Pre-Session DCS | -.90 | Standard Error .13 | score on a scale | |
| Social Anxiety Symptom Severity | Placebo | -.39 | Standard Error .14 | score on a scale | |
| Social Anxiety Symptom Severity | Non-Tailored Post-Session DCS | -.88 | Standard Error .14 | score on a scale |
Source ClinicalTrials.gov
Participant flow12
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Tailored Post-Session DCS | 40 | |
| Overall Study | STARTED | Pre-Session DCS | 38 | |
| Overall Study | STARTED | Placebo | 38 | |
| Overall Study | STARTED | Non-Tailored Post-Session DCS | 36 | |
| Overall Study | COMPLETED | Tailored Post-Session DCS | 33 | |
| Overall Study | COMPLETED | Pre-Session DCS | 33 | |
| Overall Study | COMPLETED | Placebo | 30 | |
| Overall Study | COMPLETED | Non-Tailored Post-Session DCS | 27 | |
| Overall Study | NOT COMPLETED | Tailored Post-Session DCS | 7 | |
| Overall Study | NOT COMPLETED | Pre-Session DCS | 5 |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 participant flowAdverse events4
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| serious | Serious Adverse Event | Psychiatric disorders | Tailored Post-Session DCS | 0 | 40 | |
| serious | Serious Adverse Event | Psychiatric disorders | Pre-Session DCS | 0 | 38 | |
| serious | Serious Adverse Event | Psychiatric disorders | Placebo | 1 | 38 | |
| serious | Serious Adverse Event | Psychiatric disorders | Non-Tailored Post-Session DCS | 0 | 36 |
Source ClinicalTrials.gov
Adverse event totals12
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Tailored Post-Session DCS | 0 | 40 |
| Total, all-cause mortality | Pre-Session DCS | 0 | 38 |
| Total, all-cause mortality | Placebo | 0 | 38 |
| Total, all-cause mortality | Non-Tailored Post-Session DCS | 0 | 36 |
| Total, other adverse events | Tailored Post-Session DCS | 0 | 40 |
| Total, other adverse events | Pre-Session DCS | 0 | 38 |
| Total, other adverse events | Placebo | 0 | 38 |
| Total, other adverse events | Non-Tailored Post-Session DCS | 0 | 36 |
| Total, serious adverse events | Tailored Post-Session DCS | 0 | 40 |
| Total, serious adverse events | Pre-Session DCS | 0 | 38 |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 adverse event totalsPapers6
The papers the trial lists on ClinicalTrials.gov.
Grants1
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years |
|---|---|---|---|---|---|
| R34MH099318 | 3/3-Dose Timing of D-cycloserine to Augment CBT for Social Anxiety Disorder | SMITS, JASPER | UNIVERSITY OF TEXAS AT AUSTIN | NATIONAL INSTITUTE OF MENTAL HEALTH | 2014 to 2016 |
Source NIH RePORTER
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02066792
GET https://conductscience.org/api/trials/v1/NCT02066792/registered